SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing a sharp sell-off driven by a high-profile analyst downgrade and investor rotation as participants pivot toward the potential SpaceX IPO. The community remains deeply divided, with bears pointing to stretched valuations and delivery challenges while bulls dismiss the volatility as a coordinated short attack aimed at accumulating shares ahead of future company milestones.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating significant buzz due to its ultra-low circulating supply of 19 million coins and a market cap that supporters view as severely undervalued. The community is actively discussing the potential for a massive price surge driven by scarcity and upcoming integrations in the DePin and DeFi sectors, with many investors advocating for a buy-and-hold strategy to trigger a supply shock.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing significant market interest following a higher-than-expected final Medicare Advantage rate hike, which investors view as a critical relief catalyst for the managed care sector. While some market participants are celebrating this as a potential floor for the stock, community sentiment remains split, with many analysts and traders debating whether this news is enough to overcome ongoing regulatory headwinds and persistent sector volatility.

Inflection Point Acquisition Corp. IV is a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Andrew Stephen Gundlach and Michel Combes on June 24, 2024 and is headquartered in New York, NY.

Merlin Inc.

Investors are closely monitoring Merlin Inc. as the company expands its leadership team and advances high-stakes autonomous flight contracts with the U.S. Department of Defense. Community sentiment remains split, with bulls highlighting the potential of its aircraft-agnostic software while bears express skepticism toward the company's long-term certification roadmap and valuation.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing extreme volatility and intense community frustration as participants debate its long-term viability amid ongoing price declines and regulatory uncertainty. While some users are aggressively averaging down and holding onto their positions in hopes of a future turnaround driven by institutional adoption, others are actively exiting, labeling the project a disappointment compared to broader market performance.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest shares are facing significant downward pressure following a fourth-quarter revenue miss and weak forward guidance, with leadership citing tariff-related headwinds impacting retail ad spend. The community remains deeply divided, with some investors viewing the pullback as a buying opportunity given the company's strong cash position, while vocal critics are calling for management changes or an immediate buyout due to continued execution concerns.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a major focus for traders as it navigates institutional scrutiny and a broader crypto market consolidation, with community discussions heavily split between optimism over its developer ecosystem and skepticism surrounding high-profile DeFi exploits. While bulls are leveraging the platform's utility and developer momentum to call for long-term accumulation, concerns regarding stablecoin market share and recurring network security headlines keep volatility high among retail investors.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is experiencing heightened volatility as investors weigh the escalating geopolitical tensions in the Middle East against the market's reaction to potential diplomatic deadlines. Community discussions are centered on whether incoming announcements will trigger a major correction or continue the pattern of dip-buying, with participants debating the impact of energy infrastructure threats on broader inflation and market stability.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana shares are rallying following the finalized 2027 Medicare Advantage payment rates, which exceeded analyst expectations and alleviated major concerns regarding revenue pressure for the sector. The community is actively discussing the stock's significant after-hours pop, with many debating whether this represents a sustainable turnaround or a temporary relief rally for the heavily beaten-down insurance space.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing heightened community discussion as traders monitor the company's Yartemlea commercial rollout and upcoming earnings, while simultaneously weighing the impact of aggressive short interest against potential catalysts like pending EU approval and a lucrative partnership with Novo Nordisk. Investors are closely tracking institutional accumulation patterns and the potential for a short-term squeeze, emphasizing the company's valuation gap relative to its revenue-generating status and pipeline depth.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BCLI This seems like such a sleeper.  Company DTR yet have a clear path for a confirmatory trial following approval off the CP.  I mean sure there’s risk with the FDA but they have effectively de-risked every other area with the FDA.  The only big risk is a significant raise required for the trial assuming FDA says no, but man that just seems like 180 from where they are aligned with approvals right now.  It’s essentially totality vs substantial/rigor.  I guess actions speak louder than words but this FDA has been trying to separate itself from substantial/rigor in rare disease with unmet need.

Jack Ryan

afc2881

Investo Mann

Randall S Bostrom

Anon

StockTwits for iOS

Brainstorm Cell Therapeutics, Inc.

 This seems like such a sleeper.  Company DTR yet have a clear path for a confirmatory trial following approval off the CP.  I mean sure there’s risk with the FDA but they have effectively de-risked every other area with the FDA.  The only big risk is a significant raise required for the trial assuming FDA says no, but man that just seems like 180 from where they are aligned with approvals right now.  It’s essentially totality vs substantial/rigor.  I guess actions speak louder than words but this FDA has been trying to separate itself from substantial/rigor in rare disease with unmet need.

Immutep LTD ADR

SELLAS Life Sciences Group Inc

Fate Therapeutics Inc

ImmunityBio Inc

Iovance Biotherapeutics Inc

Autolus Therapeutics Ltd - ADR

Vir Biotechnology Inc

AshvsEvilDead

@AshvsEvilDead Way to  go.  A  brief  review  of  risks and  rewards.Does  your  moniker  stand  for  Asheville?

StockTwits Web

 Way to  go.  A  brief  review  of  risks and  rewards.Does  your  moniker  stand  for  Asheville?